drugset

drugset / Trial / NCT00041652

Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer

NCT00041652 ↗

Phase 1/2 Completed 30 enrolled Gilead Sciences

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this trial is to determine the safety of hMN14 at different dose levels in the treatment of either colorectal or breast cancer.

Timeline

Start: 2000-02
Primary completion: —
Completion: 2003-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	labetuzumab	Monoclonal antibody	—	—

Indications